BRPI0908229A2 - método para dispensar iontoforeticamente um corticoesteróide, derivado de corticoesteróide, pró-droga ou sal no olho de um paciente, kit para dispensar iontoforeticamente dexametasona no olho de um paciente, formulação de dexametasona, dispositivo para dispensar dexametasona, e, método para tratar uma doença oftálmica sensível a corticoesteróide em um mamífero. - Google Patents

método para dispensar iontoforeticamente um corticoesteróide, derivado de corticoesteróide, pró-droga ou sal no olho de um paciente, kit para dispensar iontoforeticamente dexametasona no olho de um paciente, formulação de dexametasona, dispositivo para dispensar dexametasona, e, método para tratar uma doença oftálmica sensível a corticoesteróide em um mamífero.

Info

Publication number
BRPI0908229A2
BRPI0908229A2 BRPI0908229A BRPI0908229A BRPI0908229A2 BR PI0908229 A2 BRPI0908229 A2 BR PI0908229A2 BR PI0908229 A BRPI0908229 A BR PI0908229A BR PI0908229 A BRPI0908229 A BR PI0908229A BR PI0908229 A2 BRPI0908229 A2 BR PI0908229A2
Authority
BR
Brazil
Prior art keywords
corticosteroid
dexamethasone
dispensing
iontophoretically
eye
Prior art date
Application number
BRPI0908229A
Other languages
English (en)
Inventor
Cook Gary
Jaffe Mike
Patane Mike
Calias Perry
Original Assignee
Eyegate Pharma S A S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eyegate Pharma S A S filed Critical Eyegate Pharma S A S
Publication of BRPI0908229A2 publication Critical patent/BRPI0908229A2/pt
Publication of BRPI0908229A8 publication Critical patent/BRPI0908229A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
    • A61N1/0448—Drug reservoir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/20—Applying electric currents by contact electrodes continuous direct currents
    • A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
    • A61N1/303—Constructional details
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
    • A61N1/0432—Anode and cathode
    • A61N1/044—Shape of the electrode

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Electrotherapy Devices (AREA)
  • Steroid Compounds (AREA)
BRPI0908229A 2008-02-25 2009-02-24 Uso de um corticosteróide, derivado de corticosteróide, pró-fármaco ou sal deste, kit e dispositivo para dispensar iontoforeticamente um corticosteróide, derivado de corticosteróide, pró-fármaco ou sal deste no olho de um paciente para tratar um distúrbio ocular mediado por inflamação no referido paciente, e, formulação apropriada para dispensação iontoforética ocular de um corticosteróide, derivado de corticosteróide, pró-fármaco ou sal deste no olho de um paciente BRPI0908229A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3126708P 2008-02-25 2008-02-25
US4795008P 2008-04-25 2008-04-25
PCT/US2009/034977 WO2009108626A2 (en) 2008-02-25 2009-02-24 Enhanced delivery of a therapeutic to ocular tissues through iontophoresis

Publications (2)

Publication Number Publication Date
BRPI0908229A2 true BRPI0908229A2 (pt) 2017-06-13
BRPI0908229A8 BRPI0908229A8 (pt) 2017-10-10

Family

ID=41016683

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0908229A BRPI0908229A8 (pt) 2008-02-25 2009-02-24 Uso de um corticosteróide, derivado de corticosteróide, pró-fármaco ou sal deste, kit e dispositivo para dispensar iontoforeticamente um corticosteróide, derivado de corticosteróide, pró-fármaco ou sal deste no olho de um paciente para tratar um distúrbio ocular mediado por inflamação no referido paciente, e, formulação apropriada para dispensação iontoforética ocular de um corticosteróide, derivado de corticosteróide, pró-fármaco ou sal deste no olho de um paciente

Country Status (10)

Country Link
US (4) US20090306579A1 (pt)
EP (1) EP2249921B1 (pt)
JP (1) JP2011512903A (pt)
CN (1) CN101970042A (pt)
AU (1) AU2009219426B2 (pt)
BR (1) BRPI0908229A8 (pt)
CA (1) CA2716390C (pt)
IL (1) IL207014A0 (pt)
MX (1) MX2010009157A (pt)
WO (1) WO2009108626A2 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010009157A (es) 2008-02-25 2010-09-24 Eyegate Pharma S A S Suministro mejorado de un agente terapeutico para tejidos oculares a traves de iontoforesis.
MX2011006925A (es) 2008-12-31 2011-07-28 Eyegate Pharma S A S Sistema y metodo de iontoforesis ocular con amortiguacion.
JP2014503552A (ja) * 2011-01-12 2014-02-13 ソーフト イタリア エスピーエー 円錐角膜の処置のためのイオン導入による架橋剤の角膜送達および関連眼科組成物
WO2012162459A1 (en) * 2011-05-26 2012-11-29 Pepose Jay Device and method for administering eye medications
JP5463511B1 (ja) * 2013-05-13 2014-04-09 株式会社メディカル・アート イオン泳動式皮膚感染症治療装置
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
CN106413642B (zh) * 2014-04-23 2019-03-08 塞罗斯医学有限责任公司 真空辅助药物递送装置
EP3193827A1 (en) * 2014-08-13 2017-07-26 The Johns Hopkins University Glucocorticoid-loaded nanoparticles for prevention of corneal allograft rejection and neovascularization
WO2016100972A2 (en) * 2014-12-19 2016-06-23 Kemin Industries, Inc. Intraocular delivery of bioactive molecules using iontophoresis
MX2017009193A (es) 2015-01-22 2017-12-12 Eyegate Pharmaceuticals Inc Lente de contacto iontoforetica.
ES2952700T3 (es) * 2015-03-05 2023-11-03 Theianova Ltd Composiciones oftálmicas y métodos de uso de las mismas
US11806520B2 (en) 2017-10-31 2023-11-07 Tusker Medical, Inc. Systems, apparatus, and methods for delivery of therapeutic substance to nasal cavity
JP7291220B2 (ja) 2018-11-21 2023-06-14 トレモ― ファーマシューティカルズ，インコーポレーテッド ロフェコキシブの精製形態、製造方法および使用
US11161833B1 (en) 2021-04-09 2021-11-02 Tremeau Pharmaceuticals, Inc. Deuterated etoricoxib, methods of manufacture, and use thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4221787A (en) * 1978-03-28 1980-09-09 Interx Research Corporation Esteramide prodrugs of anti-inflammatory corticosteroids
US4279900A (en) * 1978-07-13 1981-07-21 Intrex Research Corporation Prodrugs for the improved delivery of halogen-containing glucocorticosteroids
US4456602A (en) * 1982-08-23 1984-06-26 The Upjohn Company Amine containing ester prodrugs of corticosteroids
US4443440A (en) * 1982-08-30 1984-04-17 The Upjohn Company Amine containing ester prodrugs of corticosteroids
US4472392A (en) * 1983-01-21 1984-09-18 The Upjohn Company Sulfonate containing ester prodrugs of corticosteroids
US4469689A (en) * 1983-03-30 1984-09-04 The Upjohn Company Sulfonate containing ester prodrugs of corticosteroids
US4588718A (en) * 1984-03-28 1986-05-13 The Upjohn Company Carboxy containing ester prodrugs of corticosteroids
GB9024005D0 (en) * 1990-11-05 1990-12-19 British Bio Technology Process for amplifying nucleic acid
US5222936A (en) * 1991-09-25 1993-06-29 Stephen Robert L Intracorporeal iontophoretic method
DE4236237A1 (de) * 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
EP0647450A1 (en) * 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
ATE195127T1 (de) * 1993-09-29 2000-08-15 Nissin Food Products Ltd In stellung 21 substituierte steroide
US6650934B2 (en) * 1996-12-17 2003-11-18 Alza Corp Polymeric foam reservoirs for an electrotransport delivery device
US6050934A (en) * 1997-02-26 2000-04-18 Cv Dynamics, Inc. Urinary catheter having palpitatable discharge valve with protective shoulders
US6090800A (en) * 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
CN1063944C (zh) * 1997-04-14 2001-04-04 齐鲁制药厂 眼用复方妥布霉素混悬液的制法
FR2773320B1 (fr) * 1998-01-05 2000-03-03 Optisinvest Dispositif pour le transfert intraoculaire de produits actifs par iontophorese
JP2000316991A (ja) * 1999-05-13 2000-11-21 Hisamitsu Pharmaceut Co Inc イオントフォレーシス装置の電極構造体及びその製造方法
JP4414517B2 (ja) 1999-09-01 2010-02-10 久光製薬株式会社 イオントフォレーシス用デバイス構造体
AU776609B2 (en) * 1999-09-24 2004-09-16 Novartis Ag Topical suspension formulations containing ciprofloxacin and dexamethasone
US6395756B2 (en) * 1999-12-23 2002-05-28 Novartis Ag Use of ophthalmic agent
US6697668B2 (en) 2001-01-25 2004-02-24 Iomed, Inc. Ocular iontophoretic device and method for using the same
US20030023228A1 (en) * 2001-07-20 2003-01-30 Parkinson Thomas M. Ocular iontophoretic device and method for using the same
EP1596823A2 (en) * 2003-02-21 2005-11-23 Sun Pharmaceuticals Industries Ltd. A stable ophthalmic composition
JP3493359B1 (ja) * 2003-03-20 2004-02-03 宣美 辛島 イオン泳動式治療装置
FR2855761B1 (fr) * 2003-06-03 2006-02-24 Optis France Sa Dispositif oculaire de delivrance variable de principes actifs par iontophorese
JP4820647B2 (ja) * 2003-08-29 2011-11-24 久光製薬株式会社 イオントフォレーシス投与組成物
EP1755616B1 (en) * 2004-04-08 2013-08-14 Advanced Ocular Systems Limited Treatment of exudative retinopathy with mineralcorticoids
FR2869531B1 (fr) * 2004-04-30 2006-07-14 Optis France Sa Sa Dispositif de iontophorese oculaire diminuant les irritations
US20060110428A1 (en) 2004-07-02 2006-05-25 Eugene Dejuan Methods and devices for the treatment of ocular conditions
WO2006072887A1 (en) 2005-01-05 2006-07-13 Eyegate Pharma Sa Ocular iontophoresis device for delivering sirna and aptamers
US8386030B2 (en) * 2005-08-08 2013-02-26 Tti Ellebeau, Inc. Iontophoresis device
US8099162B2 (en) * 2005-11-29 2012-01-17 Eyegate Pharma, S.A.S. Ocular iontophoresis device
US7767217B2 (en) * 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
US8048448B2 (en) * 2006-06-15 2011-11-01 Abbott Cardiovascular Systems Inc. Nanoshells for drug delivery
US20080027371A1 (en) * 2006-07-26 2008-01-31 Higuchi John W Method and device for minimally invasive site specific ocular drug delivery
EP2089036A1 (en) * 2006-11-02 2009-08-19 Riolan Technologies, Inc. Methods of treating an ocular allergy with low dose dexamethasone
MX2010009157A (es) 2008-02-25 2010-09-24 Eyegate Pharma S A S Suministro mejorado de un agente terapeutico para tejidos oculares a traves de iontoforesis.
CA2723458C (en) * 2008-05-14 2014-01-28 Otonomy, Inc. Controlled release corticosteroid compositions and methods for the treatment of otic disorders

Also Published As

Publication number Publication date
US20120283231A1 (en) 2012-11-08
MX2010009157A (es) 2010-09-24
CN101970042A (zh) 2011-02-09
BRPI0908229A8 (pt) 2017-10-10
US20160263024A1 (en) 2016-09-15
EP2249921B1 (en) 2020-06-17
US20090306579A1 (en) 2009-12-10
US9820935B2 (en) 2017-11-21
WO2009108626A2 (en) 2009-09-03
US10376463B2 (en) 2019-08-13
US9149525B2 (en) 2015-10-06
CA2716390C (en) 2016-08-23
EP2249921A2 (en) 2010-11-17
JP2011512903A (ja) 2011-04-28
CA2716390A1 (en) 2009-09-03
AU2009219426B2 (en) 2015-12-03
WO2009108626A3 (en) 2010-01-07
AU2009219426A1 (en) 2009-09-03
US20140046242A1 (en) 2014-02-13
IL207014A0 (en) 2010-12-30
EP2249921A4 (en) 2015-02-11

Similar Documents

Publication Publication Date Title
BRPI0908229A2 (pt) método para dispensar iontoforeticamente um corticoesteróide, derivado de corticoesteróide, pró-droga ou sal no olho de um paciente, kit para dispensar iontoforeticamente dexametasona no olho de um paciente, formulação de dexametasona, dispositivo para dispensar dexametasona, e, método para tratar uma doença oftálmica sensível a corticoesteróide em um mamífero.
BRPI1011031A2 (pt) sal de arginina de um agente ativo, composição líquida ou em gel farmaceuticamente aceitável, kit, método para tratamento de uma desordem neurológica e método para tratar ou amenizar a doença de parkinson em um paciente que necessite deste.
WO2007103373A3 (en) Compositions and methods for the treatment of immunoinflammatory disorders
BRPI0810118A2 (pt) Método para tratar doença, método para efetuar profilaxia contra caa, uso de um agente, método para reduzir amilóide vascular em um paciente, e, kit para tratamento
DK1864668T3 (da) Anvendelse af prodrug til okulær, intravitreal administration
FR2933582B1 (fr) Dispositif de traitement des matieres keratiniques humaines
WO2010068281A3 (en) Contact lens drug delivery device
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
BRPI0915893A8 (pt) métodos e aparelho para introdução de um dispositivo médico dentro do corpo de um paciente
BRPI0919920A2 (pt) compostos para tratamento de doenças e desordens oftálmicas
WO2014178931A8 (en) Sobetirome in the treatment of myelination diseases
BRPI0909082A2 (pt) imidazoquinolinas e derivados de pirimidina como moduladores potentes de processos angiogênicos acionados por vegf
FR2932979B1 (fr) Dispositif introducteur s'etendant entre un point proximal et un point distal et necessaire de traitement associe.
PL3251638T3 (pl) Urządzenie planujące dla aparatu leczniczego do stosowania w chirurgii oka
BR112013029713A2 (pt) método de tratamento de distúrbios da visão
BR112012002001A2 (pt) método para tratar uma doença e/ou distúrbio do olho, formulação farmacêutica, e, kit
EP2019646A4 (en) METHOD, DEVICE AND SYSTEM FOR THE RELEASE OF A THERAPEUTIC ACTIVE IN THE EYE
EP2147633A4 (en) METHOD AND METHOD FOR MEASURING EYESHADOW OR EYE LIGHT TRANSPORT BY RECORDING AND PROCESSING NETWORK SKIN IMAGES
BRPI0922452A2 (pt) composto, composição farmacêutica, uso em um composto, e método para prevenir, tratar ou melhorar doenças ou condições dérmicas, ou distúrbios de ferimento cutâneo agudos ou crônicos.
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
BRPI0917440A2 (pt) composições farmacêuticas oftálmicas para o tratamento de patologias neoangiogênicas do olho
BR112012002246A2 (pt) composto, composto ou sal farmaceutico aceitavel deste, composição farmaceutica, metodo para inibir, tratar e/ou reduzir o declinio cognitivol e/ou doença de akzhmer em um paciente
BRPI0718041A2 (pt) Antagonista do receptor da angiotensina ii para prevenção ou tratamento de doenças sistêmicas em gatos
BRPI0920170A2 (pt) métodos para diminuir a quantidade de partículas ldl pequenas e densas e de níveis de triglicerídeos e ldl no sangue em um humano, e para identificar um indivíduo candidato para tratamento com um composto ou um sal, prodroga ou isômero do mesmo, composto ou um sal, prodroga ou isômero do mesmo, e método.
AR077951A1 (es) Unidad dispensadora de lentes, metodo y soluciones oftalmicas

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: EYEGATE PHARMACEUTICALS, INC. (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: A61N 1/30

Ipc: A61N 1/04 (1968.09), A61K 9/00 (1968.09), A61K 31/

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A61N 1/04 , A61K 9/00 , A61K 31/573 , A61N 1/30 , A61K 41/00 , A61F 9/00

Ipc: A61K 31/573 (2006.01), A61K 9/00 (2006.01), A61N 1

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL